Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1991 Sep;33(5):346–349. doi: 10.1007/BF01756601

Treatment of chemically induced autochthonous rat mammary and colorectal carcinomas with interleukin-2

Martin R Berger 1,✉, Margaretha Salas 2, Felix Garzon 1, Edgar Petru 1, Udo Schwulera 3, Dietrich Schmähl 1
PMCID: PMC11038629  PMID: 1868493

Abstract

The antineoplastic efficacy of human interleukin-2 (IL-2) in autochthonous methylnitrosourea-induced mammary carcinoma and in acetoxymethly-methylnitrosamine-induced colorectal carcinoma of Sprague Dawley rats has been investigated. Under the conditions applied, IL-2 was non-toxic. In the mammary carcinoma IL-2 was therapeutically inactive. In the colorectal carcinoma, 1200 U IL-2/day exhibited significant antitumour activity in established tumours as well as in tumours treated “prophylactically” before their manifestation (P <0.05). The effect of IL-2 seemed to be more pronounced when given before manifestation of colorectal tumours (T/C = 8.7% vs 17.8% in established tumours). The differential sensitivity of the autochthonous mammary and colorectal carcinoma may be explained by differences in their proliferation rates and differences in volumes at the beginning of IL-2 therapy. IL-2 seems to be preferentially active in small tumours with a low proliferation rate, a feature typical of colon tumours

Key words: Rat mammary carcinomas, Colorectal carcinoma, Interleukin-2

References

  • 1.Agah R, Malloy B, Sherrod A, Bean P, Girgis E, Mazumder A. Therapy of disseminated NK-resistant tumour by the synergistic effects of recombinant interleukin-2 and tumour necrosis factor. J Biol Response Mod. 1988;7:140–151. [PubMed] [Google Scholar]
  • 2.Belardelli F, Ciolli V, Testa U, Montesoro E, Bulgarini D, Proietti E, Borghi P, Sestili P, Locardi C, Peschle C, Gresser I. Antitumour effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors. Int J Cancer. 1989;44:1108–1116. doi: 10.1002/ijc.2910440629. [DOI] [PubMed] [Google Scholar]
  • 3.Berger MR, Habs M, Schmähl D. Noncarcinogenic chemotherapy with a combination of vincristine, methotrexate and 5-fluorouracil (VMF) in rats. Int J Cancer. 1983;32:231–236. doi: 10.1002/ijc.2910320215. [DOI] [PubMed] [Google Scholar]
  • 4.Berger MR, Bischoff H, Fritschi E, Henne T, Herrmann M, Pool B, Satzinger G, Schmähl D, Weiershausen U. Synthesis, toxicity, and therapeutic efficacy of 4-amino-N-(2′-aminophenyl)-benzamide: a new compound preferentially active in slowly growing tumors. Cancer Treat Rep. 1985;69:1415–1424. [PubMed] [Google Scholar]
  • 5.Berger MR, Bischoff H, Garzon FT, Schmähl D. Autochthonous, acetoxymethyl-methylnitrosamine-induced colorectal cancer in rats: a useful tool in selecting new active antineoplastic compounds? Hepatogastroenterology. 1986;33:227–234. [PubMed] [Google Scholar]
  • 6.Berger MR, Petru E, Schmähl D. Therapeutic ratio of mono or combination bacterial lipopolysaccharide therapy in methylnitrosourea-induced rat mammary carcinoma. J Cancer Res Clin Oncol. 1987;113:437–445. doi: 10.1007/BF00390037. [DOI] [PubMed] [Google Scholar]
  • 7.Dunn OJ. Multiple comparison using rank sums. Technometrics. 1964;6:241–252. [Google Scholar]
  • 8.Eggermont A, Sugarbaker P. Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model. Br J Cancer. 1988;58:410–414. doi: 10.1038/bjc.1988.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Garzon F, Salas M, Berger MR, Kirchner H. Effect of interleukin-2 on the manifestation and growth of acetoxymethyl-methylnitrosamine-induced colorectal rat adenocarcinoma. J Cancer Res Clin Oncol. 1986;111:79–81. doi: 10.1007/BF00402782. [DOI] [PubMed] [Google Scholar]
  • 10.Habs M. Tierexperimentelle Studien zum Wirksamkeitsnachweis und zur Verträglichkeit biologisch aktiver Substanzen. In: Schuff-Werner P, Pfitzenmaier K, editors. Aktuelle Onkologie Bd 24. München: Zuckschwerdt; 1985. pp. 43–51. [Google Scholar]
  • 11.Hosokawa M, Sawamura Y, Morikage T, Okada F, Xu Z, Morikawa K, Itoh K, Kobayashi H. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide. Cancer Immunol Immunother. 1988;26:250–256. doi: 10.1007/BF00199937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hosokawa M, Yabiku T, Ikeda J, Sawamura Y, Okada F, Komatsumoto M, Tanabe T, Kobayashi H. Effects of a combination of cyclophosphamide and human recombinant interleukin 2 on pulmonary metastasis after the surgical removal of a 3-methylcholantrene-induced primary tumour in autochthonous mice. Jpn J Cancer Res. 1988;79:1147–1154. doi: 10.1111/j.1349-7006.1988.tb01538.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Iigo M, Sakurai M, Tamura T, Saijo N, Hoshi A. In vivo antitumour activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res. 1988;48:260–264. [PubMed] [Google Scholar]
  • 14.Kedar E, Ben-Aziz R, Epstein E, Leshem B. Chemo-immunotherapy of murine tumors using interleukin-2 and cyclophosphamide. Cancer Immunol Immunother. 1989;29:74–78. doi: 10.1007/BF00199920. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Koziol A, Donna A. A distribution free test for tumour growth curve analysis with application to an animal tumor immunotherapy experiment. Biometrics. 1981;37:383–390. [PubMed] [Google Scholar]
  • 16.Lee K, O'Donnell R, Marquis D, Cockett A. Eradication of palpable intradermal murine bladder tumours by systemic interleukin-2 and cyclophosphamide in C3H mice. J Biol Response Mod. 1988;7:32–42. [PubMed] [Google Scholar]
  • 17.Maekawa R, Matsumoto M, Kitagawa T, Harada M, Sato K. Effect of recombinant interleukin 2 on in vivo growth of murine myeloma X5563. Cancer Immunol Immunother. 1986;23:25–30. doi: 10.1007/BF00205551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Mitsunaga S, Kimura H, Yamaguchi Y, Mikata A. Effect of recombinant human interleukin 2 on the growth of a BALB/c sarcoma induced by moloney murine sarcoma virus. Jpn J Cancer Res. 1988;79:965–972. doi: 10.1111/j.1349-7006.1988.tb00062.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Oldham R, Fidler I, Talmadge J. Screening of biologicals and biological response modifiers. In: Schuff-Werner P, Pfitzenmaier K, editors. Aktuelle Onkologie, Bd. 24. München: Zuckschwerdt; 1985. pp. 93–109. [Google Scholar]
  • 20.Oliver R. The clinical potential of interleukin-2. Br J Cancer. 1988;58:405–409. doi: 10.1038/bjc.1988.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ootsu K, Gotoh K, Houkan T. Therapeutic efficacy of human recombinant interleukin-2 alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors. Cancer Immunol Immunother. 1989;30:71–80. doi: 10.1007/BF01665956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Papa M, Yang J, Vetto J, Shiloni E, Eisenthal A, Rosenberg S. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors. Cancer Res. 1988;48:122–129. [PubMed] [Google Scholar]
  • 23.Reissmann T, Hilgard P, Voegeli R, Zeller J. Evidence of a role for NK cells in oxazaphosphorine-mediated tumor regression. J Cancer Res Clin Oncol. 1989;115:525–530. doi: 10.1007/BF00391352. [DOI] [PubMed] [Google Scholar]
  • 24.Rodolfo M, Salvi C, Bassi C, Parmiani G. Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Cancer Immunol Immunother. 1990;31:28–36. doi: 10.1007/BF01742492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Rosenberg S, Mule J, Spiess P, Reichert C, Schwarz S. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985;161:1169–1188. doi: 10.1084/jem.161.5.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Rossio JL, Thurman GB, Long C, Vargosko A, Pinsky C. The BRMP IL-2 reference reagent. Lymphokine Res. 1986;5(Suppl 1):13–18. [PubMed] [Google Scholar]
  • 27.Schmähl D, editor. Maligne Tumoren. Aulendorf: Editio Cantor; 1981. [Google Scholar]
  • 28.Thompson J, Peace D, Klarnet J, Kern D, Greenberg P, Cheever M. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2. J Immunol. 1986;137:3675–3680. [PubMed] [Google Scholar]
  • 29.Vaage J. Local interleukin 2 therapy of mouse mammary tumors of various immunogenicities. Cancer Res. 1988;48:2193–2197. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES